By Colin Kellaher
Shares of Sangamo Therapeutics rose sharply in premarket trading Thursday after the genetic-medicine company said it inked a potentially lucrative licensing agreement with Japan's Astellas Pharma.
Sangamo said it will receive a $20 million upfront license fee from Astellas and will be eligible to earn up to an additional $1.3 billion in licensed target fees and milestone payments under the agreement, along with royalties on sales of products emerging from the deal.
The Richmond, Calif., company said the agreement gives Astellas a license to use its novel proprietary capsid, STAC-BBB, for one neurological disease target, with the right to add up to four more targets.
Sangamo shares, which closed Wednesday at $2.35, were recently up 23% to $2.90 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 19, 2024 06:20 ET (11:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。